RT Journal Article
SR Electronic
T1 Designing and implementing state-level fertility preservation health insurance benefit mandates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.13.21258849
DO 10.1101/2021.06.13.21258849
A1 Flores, Ricardo E.
A1 Yoeun, Sara W.
A1 Mesina, Omar
A1 Kaiser, Bonnie N.
A1 McMenamin, Sara B.
A1 Su, H. Irene
YR 2021
UL http://medrxiv.org/content/early/2021/06/16/2021.06.13.21258849.abstract
AB Objective To describe the design and implementation of state-level fertility preservation (FP) health insurance benefit mandates and regulation and to provide stakeholders with guidance on best practices, gaps, and implementation needs.Design Legal mapping and implementation framework-guided analysisSetting U.S. states with state-level fertility preservation health insurance benefit mandatesPatient(s) Individuals at risk of iatrogenic infertilityIntervention(s) State laws mandating health insurance benefit coverage for fertility preservation services.Main Outcome Measure(s) Design features of FP mandated benefit legislation; implementation processResult(s) Between June, 2017 and March, 2021, 11 states passed FP benefit mandate laws. On average, states took 223 days to implement their mandates from the start of the laws’ enactment dates to their corresponding effective dates, and a majority issued regulatory guidance after the law was in effect. Significant variation was observed in which FP services were specified for inclusion or exclusion in the laws and/or regulator guidance. Federal policies impacted state level implementation, with the ACA and HIPAA guiding design of fertility preservation benefits. In addition, a majority of states referenced medical society clinical practice guidelines in the design of FP mandated benefits.Conclusions Our policy scan documented significant variation in the design and implementation of health insurance benefit mandates for FP services. Future considerations for policy development include specificity and flexibility of benefit design, reference to external clinical practice guidelines to drive benefit coverage, inclusion of Medicaid populations in required coverage, and consideration of interaction with relevant state and federal policies. In addition, key considerations for implementation include the sufficient length of time for the implementation period, regulator guidance issued prior to the law going into effect, and explicit allocation of resources for the implementation process.Competing Interest StatementHIS received speaking honorarium from Ferring PharmaceuticalFunding StatementUC San Diego Moores Cancer Center, Specialized Cancer Center Support Grant NIH/NCI P30CA023100 and UC San Diego Academic Senate pilot grantAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research evaluated public programs and did not involve human subjects and thus was exempt from IRB review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are openly available via state legislature and insurance regulator websites